IMR Press / FBL / Volume 28 / Issue 3 / DOI: 10.31083/j.fbl2803047
Open Access Review
Potential Therapeutic Targets in Ovarian Cancer: Autophagy and Metabolism
Show Less
1 Department of Medical and Biological Sciences, The Catholic University of Korea, 14662 Bucheon, Republic of Korea
2 Department of Biotechnology, The Catholic University of Korea, 14662 Bucheon, Republic of Korea
3 Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA
*Correspondence: hyoon@catholic.ac.kr (Hyunho Yoon)
These authors contributed equally.
Front. Biosci. (Landmark Ed) 2023, 28(3), 47; https://doi.org/10.31083/j.fbl2803047
Submitted: 30 January 2023 | Revised: 18 February 2023 | Accepted: 1 March 2023 | Published: 10 March 2023
(This article belongs to the Special Issue Autophagy and Metabolism in Cancer)
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract

Ovarian cancer (OC) is characterized by high mortality rates owing to late diagnosis and resistance to chemotherapy. Autophagy and metabolism play essential roles in the pathological process of cancer and have recently been proposed as potential targets for anticancer therapies. Autophagy is responsible for the catabolic clearance of functionally misfolded proteins and plays different roles depending on the stage and type of cancer. Thus, understanding and controlling autophagy is relevant for treating cancer. Autophagy intermediates can communicate with each other by providing substrates for glucose, amino acid, and lipid metabolism. Metabolites and metabolic regulatory genes modulate autophagy and influence the immune response. Therefore, autophagy and the functional manipulation of metabolism during starvation or overnutrition are being investigated as potential therapeutic targets. This review discusses the role of autophagy and metabolism in OC and highlights effective therapeutic strategies targeting these processes.

Keywords
ovarian cancer
autophagy
metabolism
metabolites
cancer therapeutics
Funding
M2022B002600003/Brain Korea 21
Figures
Fig. 1.
Share
Back to top